Cocrystal Pharma, Inc. Logo

Cocrystal Pharma, Inc.

Develops novel antiviral drugs for influenza, coronaviruses, norovirus, and hepatitis C.

COCP | US

Overview

Corporate Details

ISIN(s):
US19188J4094
LEI:
Country:
United States of America
Address:
19805 N. CREEK PARKWAY, 98011 BOTHELL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that discovers and develops novel antiviral therapeutics for serious and chronic viral diseases. The company utilizes its proprietary structure-based drug design technologies and Nobel Prize-winning expertise to create antiviral drugs that target the viral replication process. Its development pipeline includes candidates for the treatment of influenza, coronaviruses (including SARS-CoV-2), norovirus, and hepatitis C. Key programs in its portfolio are at various stages of clinical development, including a Phase 2 trial for an influenza A inhibitor (CC-42344) and a Phase 1 trial for a pan-viral protease inhibitor (CDI-988) targeting norovirus and coronaviruses.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cocrystal Pharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cocrystal Pharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cocrystal Pharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SINOVAC BIOTECH LTD Logo
Biopharmaceutical firm developing vaccines against infectious diseases like COVID-19 and Hepatitis.
United States of America
SVA
Sionna Therapeutics, Inc. Logo
Developing novel NBD1 stabilizers and CFTR modulators to treat cystic fibrosis.
United States of America
SION
SK biopharmaceuticals Co., Ltd. Logo
Develops and commercializes CNS and oncology therapies for global markets, focusing on the U.S.
South Korea
326030
SK Bioscience Co.,Ltd Logo
A global biotech firm developing vaccines for diseases like COVID-19, influenza, and shingles.
South Korea
302440
Skye Bioscience, Inc. Logo
Clinical-stage biotech developing a CB1-inhibiting antibody for obesity and metabolic diseases.
United States of America
SKYE
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway
SOFTX
Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan
4597
SOLENO THERAPEUTICS INC Logo
Develops novel therapeutics for rare diseases like Prader-Willi syndrome.
United States of America
SLNO
Sol-Gel Technologies Ltd. Logo
Develops and commercializes topical dermatology drugs for acne, rosacea, and rare skin conditions.
United States of America
SLGL
Solid Biosciences Inc. Logo
Advancing gene therapies and technologies for rare neuromuscular and cardiac diseases.
United States of America
SLDB

Talk to a Data Expert

Have a question? We'll get back to you promptly.